Audited standalone and consolidated Financial Results for the half year and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vanta Bioscience Ltd reported a significant turnaround in FY2025-26 with standalone net profit of Rs 11.98 lakhs compared to a loss of Rs 265.95 lakhs in the previous year. Revenue from operations grew 61% to Rs 181.64 lakhs from Rs 112.74 lakhs. However, the company reported negative operating cash flow of Rs 521.93 lakhs (standalone), indicating cash consumption despite profitability. Total borrowings increased substantially from Rs 3,047 lakhs to Rs 3,808 lakhs year-on-year. The auditors from Mathesh & Ramana issued unmodified and unqualified opinions on both standalone and consolidated results. The Board also approved re-appointment of Managing Director Mr. Dopesh Raja Mulakala for another 3-year term.
While the company returned to profit with strong revenue growth, the negative operating cash flow and rising debt levels raise concerns about financial sustainability. Shareholders should monitor the company's ability to improve cash generation and manage its increased debt burden.